eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

without publication fees

Open access

without publication fees
2/2020
vol. 36
 
Share:
Send email
Share:
Case report

Psychotic disorders as an adverse effect of levetiracetam or discontinuation of mood stabilising drugs

Katarzyna Kurczych
1
,
Agnieszka Makulska
1
,
Iwona Kurkowska-Jastrzębska
1

  1. Institute of Psychiatry and Neurology in Warsaw
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (2), 155–163
Online publish date: 2021/12/06
Article file
- 07R_IPiN_FARM_2020-2C.pdf  [0.14 MB]
Get citation
 
 
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: APA; 2013.
2. Birger M, Swartz M, Cohen D, Alesh Y, Grishpan C, Kotelr M. Aggression: the testosterone-serotonin link. Israel Medical Association Journal. 2003; 5: 653–58.
3. Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017; 76: 24–31.
4. Chen Z, Lusicic A, O’Brien TJ, Velakoulis D, Adams SJ, Kwan P. Psychotic disorders induced by antiepileptic drugs in people with epilepsy. Brain. 2016; 139: 2668–78.
5. Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR. The prevalence of psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatry. 2014; 14: 75.
6. Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr. Bull. 2012; 38: 920–926.
7. Cramer JA, De Rue K, Devinsky O. A Systematic Review of the Behavioral Effects of Levetiracetam in Adults With Epilepsy, Cognitive Disorders, or an Anxiety Disorder During Clinical Trials. Epilepsy Behav. 2003; 4: 124-32.
8. de Almeida RM, Ferrari PF, Parmigiani S, Miczek KA. Esca lated aggressive behavior: dopamine, serotonin and GABA. European Journal of Pharmacology. 2005; 526: 51–64.
9. Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampa nel. Behav Neurol. 2018; 2018: 2064027.
10. Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochemical Pharmacology. 2003; 66: 179–89.
11. Josephson CB, Engbers JDT, Jette N, Patten SB, Singh S, Sajobi TT, et al. Prediction tools for psychiatric adverse effects after levetiracetam prescription; Epilepsy Behav. 2019; 76: 49–55.
12. Kang BS, Moon HJ, Kim YS, Lee KTS, Jung KH, Chu K, et al. The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre. Epileptic Disord 2013; 15: 302–10.
13. Köksal A, Dirican AC, Altunkaynak Y, Yildirim EA. First Manic Episode Due to Discontinuation of Valproic Acid in a Patient With Epilepsy. The Journal of Neuropsychiatry and Clinical Neurosciences. 2014; 26: E60–E61.
14. Lopez LM, Wassef AA, Molloy MS, Williams NG. Valproic Acid Induces Manifestations of Simultaneous Dopamine Enhancement and Reduction in Schizophrenia. Neuropsy chopharmacology. 2004; 29: 1217.
15. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et.al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences. 2004; 101: 9861–66.
16. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology. 2003; 61:704–06.
17. Pinckaers F, Boon ME & Majoie MHJM. Risk factors pre disposing to psychotic symptoms during levetiracetam therapy: A retrospective study. Epilepsy & Behavior. 2019; 100: 106344.
18. Sills GJ, Rogawski MA. Mechanisms of Action of Currently Used Antiseizure Drugs. Neuropharmacology. 2020; 168: 107966.
19. Sirsi D & Safdieh JE. The safety of levetiracetam. Expert Opin Drug Saf. 2007; 6: 241–50.
20. Wassef A, Baker J, Kochan LD. GABA and Schizophrenia: A Review of Basic Science and Clinical Studies. Journal of Clinical Psychopharmacology. 2003; 23: 601–640.
21. Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Psychia tric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2007; 10: 105–10.

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.